35th Anniversary Special: Nanoformulations - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

35th Anniversary Special: Nanoformulations
A look back at key nanoformulation advances and what lies ahead for nanoparticle-based drug-delivery systems.

Pharmaceutical Technology
Volume 36, Issue 7, pp. 68-69

Nanotechnology has been used to develop innovative formulations to improve bioavailability of drugs, and have found utility as carriers for either highly toxic payloads, such as chemotherapeutics, or very fragile payloads, such as proteins or nucleic acids. Panayiotis P. Constantinides, PhD, founder and principal of Biopharmaceutical and Drug Delivery Consulting, spoke to Pharmaceutical Technology about the utility of nanotechnology in formulation strategies, both past and future.

Advances in nanoparticles

PharmTech: Can you identify one or two key technical advances that have enabled the successful development of nanoparticles as drug delivery vehicles?

Panayiotis P. Constantinides, PhD, founder and principal of Biopharmaceutical and Drug Delivery Consulting, ppconstantinides@bpddc.com.
Constantinides: Within the scope of this discussion, both 1–100 nm and submicron particles (100–1000 nm) are considered as nanoparticles for both oral and non-oral drug delivery applications. The successful development of drug delivery vehicles through advances in pharmaceutical nanotechnology is certainly reflected in the marketed nanoparticulate drug products which are in the submicron range (100–1000 nm). These products include Doxil (liposomal doxorubicin, ALZA/1999), Abraxane (albumin-bound paclitaxel, Abraxis/2005) and NanoCrystal based drug products, Rapamune (Sirolimus, Wyeth/2000), Emend (aprepitant, Merck/2003) TriCor (fenofibrate, Abbott/2004), Megace ES (megestrol, Par/2004) and Invega (paliperidone palmitate, Ortho-McNeil-Janssen/2009).

Key technical advances which have enabled the successful development and commercialization of the aforementioned nanoparticulate drug products include advances in biology, materials science and particle engineering, processing, and manufacturing. Top-down and bottom-up manufacturing methods at small and large scale have been applied and tailored to the specific compound and its application. During the top-down process, high shearing homogenization or media-milling is used to reduce particle size in the presence of polymeric and surfactant stabilizers to prevent crystallization and particle growth. In the bottom-up process of manufacturing nanoparticles, the nanoparticle is created from its individual components, using precipitation, coacervation, polymerization, and hydrophobic aggregation in an effort to achieve small size by controlling the thermodynamics and kinetics of nucleation, growth, and chemical reactivity. Layer-by-layer self-assemblies using biopolymers and synthetic polymers create versatile nanostructures for drug and gene delivery. Nanoformulation is becoming an integral part of life-cycle management strategies for product line extensions and as enabling drug discovery technology for new molecular entities.

Top-down and bottom-up methods to manufacture nanoparticles have been applied to commercial products, the former for the marketed parenteral liposomal Doxil and the NanoCrystal drug products, and the latter for the albumin-bound nanoparticle Abraxane. For these drug products, advances in the characterization of nanoparticles and better understanding of how the ADME properties of compounds administered as nanoparticles are linked to particle size and surface chemistry have also contributed to their successful development and commercialization. In the case of the parenteral cancer chemotherapeutic drug products Doxil and Abraxane, key factors that have also contributed to their successful design and development were advances in nanoparticle targeting strategies based on the fundamental understanding of tumor biology principles, such as tumor vasculature and permeability, pH, and surface antigens.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here